Cartesian Therapeutics (RNAC) Cash & Equivalents (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Cash & Equivalents of $1.7 million for Q1 2026, down 99.06% year-over-year from $180.4 million in Q1 2025, and down 98.64% quarter-over-quarter from $125.1 million in Q4 2025.
Cartesian Therapeutics (RNAC) Cash & Equivalents (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Cash & Equivalents for 12 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 99.06% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 99.06% YoY), while the FY2025 annual figure was $125.1 million, down 41.14% from the prior year.
- Cash & Equivalents eased to $1.7 million in Q1 2026 per RNAC's latest filing, from $125.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $219.2 million in Q3 2024 and bottomed at $1.7 million in Q2 2025.
- Historically, Cash & Equivalents has averaged $105.8 million across 5 years, with a median of $112.0 million in 2023.
- Annual changes were most pronounced in 2024 — Cash & Equivalents surged 176.44% — and 2025, when it slumped 99.22%.
- Cartesian Therapeutics' Cash & Equivalents stood at $106.4 million in 2022, then retreated by 27.74% to $76.9 million in 2023, then soared by 176.44% to $212.6 million in 2024, then slumped by 41.14% to $125.1 million in 2025, then plunged by 98.64% to $1.7 million in 2026.
- Business Quant data shows RNAC's Cash & Equivalents at $1.7 million in Q1 2026, $125.1 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 147.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 147.61 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | 125.14 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Mar 31, 2025 | 180.43 Mn |
| Dec 31, 2024 | 212.61 Mn |
| Sep 30, 2024 | 219.20 Mn |
| Jun 30, 2024 | 87.23 Mn |
| Mar 31, 2024 | 103.42 Mn |
| Dec 31, 2023 | 76.91 Mn |
| Sep 30, 2023 | 79.60 Mn |
| Jun 30, 2023 | 112.03 Mn |
| Mar 31, 2023 | 125.93 Mn |
| Dec 31, 2022 | 106.44 Mn |
| Sep 30, 2022 | 112.84 Mn |
| Jun 30, 2022 | 138.06 Mn |
| Mar 31, 2022 | 113.44 Mn |
| Dec 31, 2021 | 114.06 Mn |
| Sep 30, 2021 | 114.65 Mn |